Special Report

Department of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, Bonn, Germany

‡Both authors contributed equally to this work

Search for more papers by this author

Amit Sharma‡

https://orcid.org/0000-0002-2216-5389

Department of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, Bonn, Germany

‡Both authors contributed equally to this work

Search for more papers by this author

Jian Hou

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Search for more papers by this author

Ingo GH Schmidt-Wolf

*Author for correspondence:

E-mail Address: Ingo.Schmidt-Wolf@ukbonn.de

Department of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, Bonn, Germany

Search for more papers by this author

Published Online:7 Dec 2023https://doi.org/10.2217/epi-2023-0373

View article

Abstract

With the recognition in the early 1960s that histones can be post-translationally modified, the list of different post-translational modifications of histones and their biological consequences has continued to expand. In addition, the idea of the ‘histone code’ hypothesis, later introduced by David Allis and colleagues, further broaden the horizon of chromatin biology. Currently, there is a wealth of knowledge about the transition between the active and the repressive state of chromatin, and modifications of histones remains at the center of chromatin biology. Histone deacetylases (HDACs) in particular are of great importance for the therapeutic success of cancer treatment. Focusing primarily on HDAC6, herein we have briefly highlighted its unique involvement in cancer and also apparently in neurodegeneration.

Plain language summary

Cancer (uncontrolled cell proliferation) and neurodegenerative diseases (loss of neurons/protein aggregation) are two distinct pathological conditions that share/overlap certain molecular determinants. Histone deacetylase 6 appears to be one such determinant for which researchers have made significant progress by accumulating sufficient evidence for its clinical translation in these aforementioned disease conditions.

Tweetable abstract

Be it cancer or neurodegeneration, understanding the dynamics of histone modifications continues to be of great interest, and histone deacetylase 6 (HDAC6) now apparently is at the forefront.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl Acad. Sci. USA 51(5), 786–794 (1964).
Medline CASGoogle Scholar
2. Jenuwein T, Allis CD. Translating the histone code. Science 293(5532), 1074–1080 (2001).
Medline CASGoogle Scholar
3. Sharma A, Liu H, Herwig-Carl MC, Chand Dakal T, Schmidt-Wolf IGH. Epigenetic regulatory enzymes: mutation prevalence and coexistence in cancers. Cancer Invest. 39(3), 257–273 (2021).
Medline CASGoogle Scholar
4. Li Y, Shin D, Kwon SH. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J. 280(3), 775–793 (2013). • Discusses why HDAC6 is unique compared with other histone deacetylase family members.
Medline CASGoogle Scholar
5. Zheng YC, Kang HQ, Wang B et al. Curriculum vitae of HDAC6 in solid tumors. Int. J. Biol. Macromol. 230, 123219 (2023).
Medline CASGoogle Scholar
6. Li T, Zhang C, Hassan S et al. Histone deacetylase 6 in cancer. J. Hematol. Oncol. 11(1), 111 (2018).
MedlineGoogle Scholar
7. LoPresti P. HDAC6 in diseases of cognition and of neurons. Cells 10(1), (2020). •• A paper on the role of HDAC6 in various signaling pathways associated with early and advanced cancers and neurological diseases.
MedlineGoogle Scholar
8. Shen S, Kozikowski AP. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014–2019). Expert Opin. Ther. Pat. 30(2), 121–136 (2020).
Medline CASGoogle Scholar
9. Pulya S, Amin SA, Adhikari N, Biswas S, Jha T, Ghosh B. HDAC6 as privileged target in drug discovery: a perspective. Pharmacol. Res. 163, 105274 (2021).
Medline CASGoogle Scholar
10. Pu J, Liu T, Sharma A, Schmidt-Wolf IGH. Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment. BMC Med. Genomics 16(1), 295 (2023).
Medline CASGoogle Scholar
11. Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J. Biomed. Biotechnol. 2011, 875824 (2011).
MedlineGoogle Scholar
12. Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 53(3), 267–277 (2008).
Medline CASGoogle Scholar
13. Van Damme M, Crompot E, Meuleman N et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 7(12), 1403–1412 (2012).
Medline CASGoogle Scholar
14. Lin XJ, Cai LM, Qian ZJ et al. Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma. Onco. Targets Ther. 10, 5129–5136 (2017).
MedlineGoogle Scholar
15. Li C, Cao L, Xu C et al. The immunohistochemical expression and potential prognostic value of HDAC6 and AR in invasive breast cancer. Hum. Pathol. 75, 16–25 (2018).
Medline CASGoogle Scholar
16. Saji S, Kawakami M, Hayashi S et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 24(28), 4531–4539 (2005).
Medline CASGoogle Scholar
17. Haakenson J, Zhang X. HDAC6 and ovarian cancer. Int. J. Mol. Sci. 14(5), 9514–9535 (2013).
MedlineGoogle Scholar
18. Yano M, Miyazawa M, Ogane N et al. Up-regulation of HDAC6 results in poor prognosis and chemoresistance in patients with advanced ovarian high-grade serous carcinoma. Anticancer Res. 41(3), 1647–1654 (2021).
Medline CASGoogle Scholar
19. Yano M, Katoh T, Miyazawa M et al. Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma. Sci. Rep. 9(1), 2397 (2019).
MedlineGoogle Scholar
20. Hou H, Zhao L, Chen W et al. Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma. Int. J. Exp. Pathol. 96(4), 248–254 (2015).
Medline CASGoogle Scholar
21. Cosenza M, Civallero M, Marcheselli L, Sacchi S, Pozzi S. Citarinostat and momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination. Apoptosis 25(5–6), 370–387 (2020).
Medline CASGoogle Scholar
22. Keremu A, Aimaiti A, Liang Z, Zou X. Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines. Cancer Chemother. Pharmacol. 83(2), 255–264 (2019).
Medline CASGoogle Scholar
23. M L, P PV, T K et al. Essential role of HDAC6 in the regulation of PD-L1 in melanoma. Mol. Oncol. 10(5), 735–750 (2016).
MedlineGoogle Scholar
24. Simoes-Pires C, Zwick V, Nurisso A, Schenker E, Carrupt PA, Cuendet M. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol. Neurodegener. 8, 7 (2013).
Medline CASGoogle Scholar
25. Trzeciakiewicz H, Ajit D, Tseng JH et al. An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline. Nat. Commun. 11(1), 5522 (2020).
Medline CASGoogle Scholar
26. Tseng CC, Huang SY, Tsai HP, Wu CW, Hsieh TH. HDAC6 is a prognostic biomarker that mediates IL-13 expression to regulate macrophage polarization through AP-1 in oral squamous cell carcinoma. Sci. Rep. 12(1), 10513 (2022).
Medline CASGoogle Scholar
27. Zhang Z, Cao Y, Zhao W, Guo L, Liu W. HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma. Cancer Biomark. 19(2), 169–175 (2017).
Medline CASGoogle Scholar
28. Hu Z, Rong Y, Li S, Qu S, Huang S. Upregulated histone deacetylase 6 associates with malignant progression of melanoma and predicts the prognosis of patients. Cancer Manag. Res. 12, 12993–13001 (2020).
Medline CASGoogle Scholar
29. Xie X, Luo K, Li Y et al. Histone deacetylase 6 expression in metastatic lymph nodes is a valuable prognostic marker for resected node-positive esophageal squamous cell cancer. Cancer Manag. Res. 10, 5451–5460 (2018).
Medline CASGoogle Scholar
30. Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in cancer immunotherapy. Mol. Cancer 19(1), 145 (2020).
Medline CASGoogle Scholar
31. Kuo IY, Yang YE, Yang PS et al. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. Theranostics 11(14), 7029–7044 (2021).
Medline CASGoogle Scholar
32. Shen M, Xu Z, Xu W et al. Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway. J. Exp. Clin. Cancer Res. 38(1), 149 (2019).
MedlineGoogle Scholar
33. Herrmann A, Lahtz C, Nagao T et al. CTLA4 promotes Tyk2-STAT3-dependent B-cell oncogenicity. Cancer Res. 77(18), 5118–5128 (2017).
Medline CASGoogle Scholar
34. Ou L, Wang H, Huang H et al. Preclinical platforms to study therapeutic efficacy of human gammadelta T cells. Clin. Transl. Med. 12(6), e814 (2022).
Medline CASGoogle Scholar
35. Stephan D, Weiher H, Schmidt-Wolf IGH. CIK cells and HDAC inhibitors in multiple myeloma. Int. J. Mol. Sci. 18(5), (2017).
Google Scholar
36. Sharma A, Schmidt-Wolf IGH. 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. J. Exp. Clin. Cancer Res. 40(1), 388 (2021).
MedlineGoogle Scholar
37. Auzmendi-Iriarte J, Saenz-Antonanzas A, Mikelez-Alonso I et al. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma. Cell Death Dis. 11(6), 417 (2020).
Medline CASGoogle Scholar
38. Han MH, Kim JM, Cheong JH et al. Efficacy of cytokine-induced killer cell immunotherapy for patients with pathologically pure glioblastoma. Front. Oncol. 12, 851628 (2022).
Medline CASGoogle Scholar
39. Kong DS, Nam DH, Kang SH et al. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget 8(4), 7003–7013 (2017).
MedlineGoogle Scholar
40. Sharma A, Wullner U, Schmidt-Wolf IGH, Maciaczyk J. Marginalizing the genomic architecture to identify crosstalk across cancer and neurodegeneration. Front. Mol. Neurosci. 16, 1155177 (2023). •• Discusses the involvement of certain common genes or shared pathways in cancers and neurodegenerative diseases.
MedlineGoogle Scholar
41. Sharma A, Liu H, Tobar-Tosse F et al. Ubiquitin carboxyl-terminal hydrolases (UCHs): potential mediators for cancer and neurodegeneration. Int. J. Mol. Sci. 21(11), (2020). •• Discusses the potential mediators for cancer and neurodegeneration.
Google Scholar
42. Rodrigues DA, Pinheiro PSM, Sagrillo FS, Bolognesi ML, Fraga CAM. Histone deacetylases as targets for the treatment of neurodegenerative disorders: challenges and future opportunities. Med. Res. Rev. 40(6), 2177–2211 (2020).
Medline CASGoogle Scholar
43. Lemos M, Stefanova N. Histone deacetylase 6 and the disease mechanisms of alpha-synucleinopathies. Front. Synaptic. Neurosci. 12, 586453 (2020).
Medline CASGoogle Scholar
44. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115(6), 727–738 (2003). • First study to report that HDAC6 had high expression in α-synuclein- and ubiquitin-positive Lewy bodies in brain sections of patients with Parkinson's disease.
Medline CASGoogle Scholar
45. Mazzocchi M, Collins LM, Sullivan AM, O'Keeffe GW. The class II histone deacetylases as therapeutic targets for Parkinson's disease. Neuronal Signal. 4(2), NS20200001 (2020).
Medline CASGoogle Scholar
46. Ding H, Dolan PJ, Johnson GV. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J. Neurochem. 106(5), 2119–2130 (2008).
Medline CASGoogle Scholar
47. Odagiri S, Tanji K, Mori F et al. Brain expression level and activity of HDAC6 protein in neurodegenerative dementia. Biochem. Biophys. Res. Commun. 430(1), 394–399 (2013).
Medline CASGoogle Scholar
48. Anderson KW, Chen J, Wang M, Mast N, Pikuleva IA, Turko IV. Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain. PLOS ONE 10(5), e0126592 (2015).
MedlineGoogle Scholar
49. Li E, Choi J, Sim HR et al. A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of Huntington's disease. BMB Rep. 56(2), 178–183 (2023).
Medline CASGoogle Scholar
50. Bohush A, Bieganowski P, Filipek A. Hsp90 and its co-chaperones in neurodegenerative diseases. Int. J. Mol. Sci. 20(20), (2019).
MedlineGoogle Scholar
51. Gupta A, Bansal A, Hashimoto-Torii K. HSP70 and HSP90 in neurodegenerative diseases. Neurosci. Lett. 716, 134678 (2020).
Medline CASGoogle Scholar
52. Depetter Y, Geurs S, De Vreese R et al. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models. Int. J. Cancer 145(3), 735–747 (2019).
Medline CASGoogle Scholar
53. Lin A, Giuliano CJ, Palladino A et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11(509), (2019).
Google Scholar
54. Medard G, Sheltzer JM. Ricolinostat is not a highly selective HDAC6 inhibitor. Nat. Cancer 4(6), 807–808 (2023).
Medline CASGoogle Scholar

Vol. 15, No. 22

Metrics

Downloaded 135 times

History

Received 25 October 2023

Accepted 21 November 2023

Published online 7 December 2023

Published in print November 2023

Information

Keywords

Author contributions

Writing, original draft: J Pu, A Sharma, J Hou & IGH Schmidt-Wolf. All authors read and approved the final manuscript.

Acknowledgments

The authors acknowledge support received from the Deutsche Krebshilfe (Bonn, Germany) and the China Scholarship Council (CSC).

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

PDF download

Histone deacetylase 6: at the interface of cancer and neurodegeneration

Abstract

Plain language summary

Tweetable abstract

References